Background {#Sec1}
==========

Preterm birth remains one of the most important causes of neonatal morbidity and mortality, despite recent considerable development of perinatal medicine \[[@CR1]\]. There are many risk factors of premature delivery, including infections, poor socioeconomic status, demographic conditions, as well as environmental and genetic effects \[[@CR2]--[@CR6]\].

Markers are required to not only classify a pregnant woman as being at risk of preterm delivery, but also for implementing adequate and effective prophylaxis. Research conducted in recent years has particularly focused on the role of markers of acute inflammation in etiology and diagnosis of premature labor \[[@CR7]--[@CR11]\].

Osteoprotegerin (OPG) is a glycoprotein that belongs to the family of tumor necrosis factor (TNF) receptors \[[@CR12]\]. OPG is produced in endothelial cells, vascular smooth muscle cells, and different cells of the immune system \[[@CR13]--[@CR17]\]. Some proinflammatory cytokines can increase this process, while glucocorticosteroids, parathormone, and fibroblast growth factor decrease this process \[[@CR18], [@CR19]\].

Receptor activator of NF-κB ligand (RANKL) is a type II cell membrane glycoprotein from the family of TNF proteins \[[@CR20]\]. In the human system, RANKL is present in three forms as a cytoplasmic molecule, as an originally membrane-bound particle, and as a free plasmatic fraction, so-called soluble RANKL (sRANKL) \[[@CR21], [@CR22]\]. RANKL is present in osteoblasts, T-lymphocytes, within peripheral lymph nodes, bones, and the fetal liver \[[@CR20]\]. Expression of the RANKL gene increases under the action of interleukin-1β, interleukin-11, TNF-α, prostaglandin E2, lipopolysaccharide D3 vitamin D3, and parathormone \[[@CR23]--[@CR25]\].

Receptor activator of nuclear factor kappa-B (NF-κB) (RANK) also belongs to the TNF family \[[@CR26], [@CR27]\]. RANK acts as a receptor for RANKL and OPG. After binding of RANK (as a receptor) with RANKL (as its ligand), the receptor undergoes trimerization, which initiates an intracellular cascade, leading to cellular activation \[[@CR26], [@CR28]\].

The OPG/RANKL/RANK system plays an important role in bone tissue function, but the reciprocal relation between OPG/RANKL/RANK and the immune system suggests that activation of the immune system in preterm labor can also noticeably affect the OPG/RANKL/RANK system \[[@CR29], [@CR30]\]. Even low levels of cytokines can influence components of the OPG/RANKL/RANK system. However, there is a paucity of scientific data to support this hypothesis.

Receptors for advanced glycation end products (RAGE) are nonspecific multiligand receptors that belong to the superfamily of immunoglobulin. Activation of RAGE induces and supports inflammatory responses, mainly by NF-κB and mitogen-activated protein kinase (MAPK) activation. \[[@CR31]--[@CR33]\].

In contrast to native RAGE, negative isoforms have also been described, including secretory RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) \[[@CR34]\]. Binding of advanced glycation end products (AGE) and some alarmines to negative RAGE fulfills an important role, preventing the toxic influence of ligand-RAGE complexes \[[@CR34], [@CR35]\].

The hypothesis of the protective role of RAGE negative variants and its ligands leads to the question of whether soluble RAGE levels in pregnancy can affect the prevalence of premature labor associated with spontaneous uterine contractility and preterm rupture of the membranes. Only a few authors have investigated RAGE in premature labor \[[@CR36]--[@CR42]\].

We therefore investigated the following. (1) The relationships between levels of sRANKL, OPG, sRAGE, and esRAGE and the interval from the diagnosis of threatened premature labor or preterm premature rupture of the fetal membranes (pPROM) to delivery and evaluated the prognostic value of parameters for preterm birth. (2) The relationships between sRANKL, OPG, sRAGE, and esRAGE levels and other parameters used in diagnosing premature labor. (3) Plasma sRANKL, OPG, sRAGE, and esRAGE levels in pregnancies complicated by threatened premature labor with and without premature rupture of the membranes.

Methods {#Sec2}
=======

This study was conducted in the Department of Obstetrics and Gynecology and in the Department of Laboratory Diagnostics and Molecular Medicine of Pomeranian Medical University from October 29, 2012 to July 30, 2014. The study was approved by the Bioethical Committee of Pomeranian Medical University (KB-0012/121/12). All women gave their written informed consent prior to their inclusion in the study. Ninety women who were between 22 and 36 weeks of gestation were included and divided into two groups. Group A comprised 41 women between 22 and 36 weeks of gestation, presenting with symptoms of threatened premature labor. Group B comprised 49 women between 22 and 36 weeks of gestation with preterm premature rupture of the membranes. The detailed characteristics of the study groups are shown in Table [1](#Tab1){ref-type="table"}. Successive patients who reported to the departments and met the criteria for inclusion were included in the study. Random selection was the method of inclusion.Table 1General characteristics of the study populationParameterGroup AGroup Bp valueNumber of women4149-Age (years)28.32 ± 6.4430 ± 6.50NSGestational age (weeks)30.9 ± 3.131.10 ± 3.76NSParity2 ± 12 ± 1NSGestational age at delivery (weeks)34.87 ± 4.0431.67 ± 3.740,001Birth weight (g)2547.48 ± 833.411939.37 ± 801.770,001Smoker (N)26NSNon-smoker (N)3943Previous history of preterm birth (N)46NSNo preterm birth history (N)3743Place of residence -- city (N)3135NSPlace of residence -- village (N)1014Excellent socioeconomic status (N)1419NSMediocre socioeconomic status (N)2730Positive cervical culture (N)1420NSNegative cervical culture (N)2729Values are mean ± standard deviation (analyzed by Student's *t*-test) or N (analyzed by *χ* ^2^ Pearson's test)

The criteria of inclusion in group A were as follows: (1) the presence of spontaneous uterine contractility between 22 and 36 weeks of gestation, with a frequency of at least four contractions per hour within at least a 2-h period, as confirmed in a tocodynamometric test; (2) cervical effacement, as shown in an ultrasound scan, with cervix length \< 25 mm; and (3) cervical maturation with a Bishop score ≥ 4. The criteria for inclusion in group B were as follows:(1) diagnosis of premature rupture of the membranes between 22 and 36 weeks of gestation; (2) confirmation of premature rupture of the membranes by a positive test result for the presence of insulin-like growth factor binding protein-1 in vaginal discharge; and (3) absence of preterm spontaneous uterine contractility with a negative tocodynamometric test result.

No later than 2 h after admission to the departments, peripheral maternal blood was sampled from the ulnar vein and put into tubes containing EDTA-K2. After centrifugation (10 min, 5000 rps), plasma samples were stored at −80 °C until measurement of sRAGE, esRAGE, sRANKL, and OPG levels.

Immunoassay methods were used to measure sRAGE, esRAGE, sRANKL,and OPG levels. Human sRAGE ELISA (Bio Vendor Research and Diagnostic Products) was used for quantitative measurement of human sRAGE levels, with a calibration range of 50--3200 pg/mL and a limit of detection at 19.2 pg/mL. Human esRAGE ELISA (Cusabio, CSB-E15773h) was used for quantitative measurement of human esRAGE. The calibration range for esRAGE was 0.625--40 ng/mL, with a limit of detection at 0.156 ng/mL. Human sRANKL (total) ELISA (Bio Vendor Research and Diagnostic Products) was used to establish sRANKL serum levels, with a calibration range of 31.25--2000 pg/mL and a limit of detection at 25 pg/mL. Human OPG ELISA (Bio Vendor Research and Diagnostic Products) was used for quantitative measurement of human OPG. The calibration range for OPG was 180--7200 pg/mL, with a limit of detection at 36 pg/mL. Coefficients of variation for the assays of OPG, sRANKL, sRAGE, and esRAGE are shown in Table [2](#Tab2){ref-type="table"}.Table 2Coefficients of variation for assays of OPG, sRANKL, sRAGE, and esRAGEAssayCoefficient of variationIntra-assay (%)Inter-assay (%)OPG3.535.78sRANKL9.3812.00sRAGE4.007.15esRAGE5.208.50

We also measured the white blood cell count, the percentage of neutrophils in venous blood, and plasma levels of C-reactive protein (CRP) and procalcitonin. In both groups, the cervical length was assessed with a vaginal probe placed in the vestibule of the vagina using ultrasound. The arithmetic mean of three subsequent measurements was used in the study. In every woman, a microbiological smear for aerobic bacteria culture was taken from the cervical canal during gynecological examination. In group A, after exclusion of diagnosis of intrauterine infection, we administered intravenous inflow of fenoterol at a dose ranging from 0.0035 to 0.005 mg/min as a tocolytic agent, until inhibition of uterine contractions. The pregnant women were also administered betamethasone in two 12-mg doses with a 24-h interval to accelerate fetal lung maturation.

Group A was categorized into subgroups by the duration of pregnancy from the diagnosis of threatened premature labor up to delivery, with a 7-day cut-off point. In group B, antibiotic agents were administered after diagnosis to extend the duration of pregnancy between rupture of the membranes and delivery. We administered 2 g of ampicillin and 300 mg of erythromycin every 6 h intravenously for 48 h. We subsequently administered 500 mg of amoxicillin every 8 h and 250 mg of erythromycin every 6 h for 5 days orally as a standard protocol. These women were also administered two 12-mg doses of betamethasone with a 24-h interval to accelerate fetal lung maturation, and we avoided administration of tocolytic agents. Group B was additionally divided into subgroups according to the duration of pregnancy from rupture of the membranes to delivery, with the cut-off point considered as 24 h.

Statistical analysis {#Sec3}
--------------------

Statistical evaluation was performed using Statistica 10.0 PL software for Windows. The distribution of variables was checked using the non-parametric Shapiro--Wilk W test, and according to the results, values were further analyzed. The level of significance was set at p \<0.05. For the presentation of non-normally distributed variables, the number of patients, range of values (minimum--maximum), median, and the first and third quartile values (Q1--Q3) were included in the descriptive statistics. The results for normally distributed variables are shown as the number of patients, arithmetical mean, and standard deviation (SD). The Mann--Whitney *U* test for unpaired variables was used to assess the differences in the studied parameters between the groups. For statistical analysis of relationships, correlation coefficients were estimated using Spearman's test. Receiver operating characteristic (ROC) curve analysis was used to determine the cut-off point, as well as the predictive value of tests, their sensitivity, specificity, and positive and negative predictive values (PPV and NPV, respectively), and accuracy. Comparison of the area under the curve (AUC) was used to compare diagnostic tests.

Results {#Sec4}
=======

The distribution of most values of the analyzed parameters was not normal (Shapiro--Wilk W-test; p \> 0.05). Descriptive statistics of the variables are shown in Table [3](#Tab3){ref-type="table"}. In group A, a positive correlation was found between sRAGE levels and the duration of pregnancy from the onset of symptoms of threatened premature labor until completion of delivery, and a negative correlation was found between sRANKL levels and the duration of pregnancy from diagnosis until delivery.Table 3Descriptive statistics of the study groupsParameterGroup AGroup BNmin--maxQ1Q3MedianNmin--maxQ1Q3MedianWBC (10^9^/L)413.32--20.069.5114.413.19498.23--25.4010.0514.3811.82CRP (mg/L)410.4--39.52.35.53.7490.2--77.32.711.85.8Band (%)4163.5--92.074.279.476.84955.7--91.066.780.871.7PCT (μg/L)400.02--0.080.030.070.05430.03--10.100.030.060.05sRAGE (pg/mL)41128.7--1686.6352.5787.5594.94948.9--4872.0297.2775.3612.9esRAGE (pg/mL)41230.0--915.2406.7533.8490.249281.1--958.8483.0610.1541.1sRANKL (pg/mL)412046.5--85,437.54374.49168.76425.0491075.0--75,875.07250.029,381.211,362.5OPG (pg/mL)41157.2--2048.4332.31449.6531.749234.2--14,520411.8867.1581.4WBC: white blood cells; CRP: C-reactive protein; Band:banded neutrophils; PCT: procalcitonin; sRAGE:secretory receptors for advanced glycation end products; esRAGE:endogenous secretory receptors for advanced glycation end products; sRANKL:soluble receptor activator of nuclear factor κB; OPG:osteoprotegerin; Q1:quartile 1; Q3:quartile 3; min:minimum; max:maximum

In group B, a positive correlation was found between sRAGE levels and the duration of pregnancy from pPROM until completion of delivery. There was also a negative correlation between sRANKL levels and the interval from pPROM until delivery (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Two-dimensional scatterplots. The scatterplots show the correlation between sRAGE and sRANKL levels and the latent time from symptoms until delivery in both study groups

In group A, a duration of pregnancy shorter than 7 days from diagnosis to delivery was accompanied by a lower sRAGE level and a higher sRANKL level (median = 405.9 pg/mL vs 744.0 pg/mL; median = 8253.1 pg/mL vs 5671.8 pg/mL, respectively, Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Box plots of Group A. Levels of sRAGE, esRAGE, OPG, and sRANKL according to latent time from symptoms until delivery. The Mann--Whitney *U*-test was used for comparison

In group B, a duration of pregnancy shorter than 24 h from pPROM until delivery was accompanied by lower sRAGE levels and higher sRANKL levels (median = 410.6 pg/mL vs 712.05 pg/mL; median = 16,428.8 pg/mL vs 7868.7 pg/mL, respectively, Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Box plots of Group B. Levels of sRAGE, esRAGE, OPG, and sRANKL according to latent time from symptoms until delivery, using the Mann--Whitney *U*-test

In group A, analysis of the AUC showed a low risk of delivery in a 7-day period from diagnosis of threatened preterm labor for sRANKL levels lower than 5963.1 pg/mL. The sensitivity was 0.895 and the NPV was 0.857. Analysis of the AUC for sRAGE showed a low risk of premature delivery in a 7-day period from diagnosis of threatened preterm labor for sRAGE levels exceeding 690.6 pg/mL. The sensitivity was 0.947 and the NPV was 0.929. Comparison of the AUC for sRAGE and sRANKL showed similar prognostic values (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4ROC curve analysis of sRAGEand sRANKL according to latent time from symptoms until delivery in group A. AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value; ACC:accuracy

In group B, analysis of the AUC for sRANKL showed that sRANKL levels lower than 12345.1 pg/mL predicted a low risk of preterm delivery in 24 h from pPROM. The sensitivity was 0.682 and the NPV was 0.741. Analysis of the AUC for sRAGE showed that when the sRAGE level was 223.92 pg/mL, the sensitivity was as low as 0.318, but the specificity and PPV reached 1.0. Comparison of the AUC for sRAGE and sRANKL showed a similar prognostic value (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5ROC curve analysis of sRAGE and sRANKL according to latent time from symptoms until delivery in group B. AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value; ACC: accuracy

High sRANKL levels were correlated with positive results of a cervical microbiological smear (r = 0.383, p = 0.013). Comparison of the rank correlations in group A is shown in Table [4](#Tab4){ref-type="table"}. In group B, high sRANKL levels were correlated with positive cervical microbiological smear findings (r = 0.356, p = 0.012) and low sRAGE levels. Comparison of rank correlations in group B is shown in Table [5](#Tab5){ref-type="table"}.Table 4Correlations between serum sRAGE, esRAGE, sRANKL, and OPG levels and other markers in group ACorrelationrpCorrelationrpesRAGE vs WBC0.149NSsRANKL vs WBC0.182NSesRAGE vs CRP0.238NSsRANKL vs CRP0.074NSesRAGE vs band0.133NSsRANKL vs band−0.094NSesRAGE vs MC−0.165NSsRANKL vs MC0.3830.013esRAGE vs PCT0.368NSsRANKL vs PCT0.051NSesRAGE vs GD0.045NSsRANKL vs GD−0.220NSesRAGE vs BW0.038NSsRANKL vs BW−0.071NSsRAGE vs WBC0.070NSOPG vs WBC−0.318NSsRAGE vs CRP−0.303NSOPG vs CRP0.3830.048sRAGE vs band−0.171NSOPG vs band0.280NSsRAGE vs MC−0.165NSOPG vs MC0.049NSsRAGE vs PCT−0.453NSOPG vs PCT0.448NSsRAGE vs GD0.4690.002OPG vs GD0.093NSsRAGE vs BW0.3380.03OPG vs BW0.072NSp: level of significance; r: Spearman's correlation; sRAGE:secretory receptors for advanced glycation end products; esRAGE:endogenous secretory receptors for advanced glycation end products; sRANKL:soluble receptor activator of nuclear factor κB; OPG:osteoprotegerin; WBC:white blood cells; CRP: C-reactive protein; band: banded neutrophils; MC: microbial culture from the cervix; PCT:procalcitonin; GD: gestational age at delivery; BW: birth weightTable 5Correlations between serum sRAGE, esRAGE, sRANKL, and OPG levels and other markers in group BCorrelationrpCorrelationrpesRAGE vs WBC−0.030NSsRANKL vs WBC0.113NSesRAGE vs CRP0.3900.020sRANKL vs CRP−0.072NSesRAGE vs band0.035NSsRANKL vs band0.218NSesRAGE vs MC−0.174NSsRANKL vs MC0.3560.012esRAGE vs PCT−0.077NSsRANKL vs PCT0.255NSesRAGE vs GD0.069NSsRANKL vs GD0.246NSesRAGE vs BW0.038NSsRANKL vs BW0.270NSsRAGE vs WBC0.012NSOPG vs WBC0.082NSsRAGE vs CRP−0.293NSOPG vs CRP0.164NSsRAGE vs band−0.202NSOPG vs band0.001NSsRAGE vs MC−0.2930.045OPG vs MC0.074NSsRAGE vs PCT−0.099NSOPG vs PCT0.301NSsRAGE vs GD0.206NSOPG vs GD−0.037NSsRAGE vs BW0.078NSOPG vs BW0.077NSp: level of significance; r: Spearman's correlation; sRAGE:secretory receptors for advanced glycation end products; esRAGE:endogenous secretory receptors for advanced glycation end products; sRANKL:soluble receptor activator of nuclear factor κB; OPG: osteoprotegerin; WBC:white blood cells; CRP: C-reactive protein; band: banded neutrophils; MC: microbial culture from the cervix; PCT: procalcitonin; GD: gestational age at delivery; BW: birth weight

The median values of esRAGE and sRANKL levels were significantly lower in group A than in group B (median = 490.2 vs 541.1 pg/mL; 6425.0 vs 11362.5 pg/mL, respectively, Fig. [6](#Fig6){ref-type="fig"}). The values of the other variables were not significantly different between the groups (Table [6](#Tab6){ref-type="table"}).Fig. 6Comparison of esRAGE and sRANKL between the groups. The Mann--Whitney *U*-test was used for comparison between the groupsTable 6Comparison ofstudy parameters between groupsParameterRank-sum group ARank-sum group BUZpWBC (10^9^/L)1213.51487.5652.50−0.077NSCRP (mg/L)1003.01625.0475.00−1.864NSBand (%)623.5504.5228.501.000NSPCT (μg/L)202.5577.5136.50−0.530NSsRAGE (pg/mL)1883.02122.0946.000.308NSesRAGE (pg/mL)1107.51973.5477.50−2.7570.005sRANKL (pg/mL)1471.52623.5610.50−3.1880.001OPG (pg/mL)1342.51660.5714.500.164NSWBC:white blood cells; CRP: C-reactive protein; Band:banded neutrophils; PCT:procalcitonin; sRAGE:secretory receptors for advanced glycation end products; esRAGE:endogenous secretory receptors for advanced glycation end products; sRANKL:soluble receptor activator of nuclear factor κB; OPG:osteoprotegerin; U:Mann--Whitney *U* test; Z:Mann--Whitney Z test; p: Mann--Whitney level of significance

Discussion {#Sec5}
==========

Many studies have focused on the role of the OPG/RANKL/RANK system, not only in osteoporosis, but also in cardiovascular and autoimmune (e.g., rheumatoid arthritis) diseases or neoplasms \[[@CR43]--[@CR49]\]. However, there is a lack of studies on assessment of components of the OPG/RANKL/RANK system in premature labor. Only a few studies have described the relationship between the OPG/RANKL/RANK system and pregnancy-induced hypertension, preeclampsia, and intrauterine growth restriction \[[@CR50]--[@CR55]\].

Negative RAGE isoforms can inhibit endogenous inflammation and their protective function has been confirmed in diabetes mellitus, some cardiovascular diseases, atherosclerosis, and in some types of neoplasms \[[@CR56]--[@CR62]\]. Only a few studies have assessed the importance of RAGE for preterm labor \[[@CR39]--[@CR42], [@CR63]\]. These studies did not clearly prove a protective function of negative soluble RAGE isoforms in such complications of pregnancy. Additionally, only a few studies evaluated RAGE and sRANKL levels in threatened preterm labor. Romero et al. assessed RAGE levels in amniotic fluid in five groups of pregnant women: (1) women with a gestational age between 14 and 18 weeks of an uncomplicated pregnancy; (2) pregnancies at term; (3) women in labor at term; (4) pregnant women threatened with premature labor with unruptured fetal membranes; and (5) women diagnosed with pPROM, depending on the presence or absence of intrauterine infection \[[@CR39]\]. The authors found that amniotic fluid sRAGE and esRAGE levels increased as pregnancy progressed, and they were positively correlated with intra-amniotic infection in preterm pregnancy. Considering the molecular patterns of RAGE function, the aforementioned findings are unexpected. However our finding of increased esRAGE levels in women who were diagnosed with pPROM is consistent with previous studies \[[@CR57], [@CR64], [@CR65]\]. Another study showed decreased RAGE levels in women with overt chorioamnionitis \[[@CR40]\]. This findingis consistent with the molecular theory of the biological function of RAGE.

These different previous findings led to our focus on analyzing biomarkers as risk factors for the outcome of preterm birth. We found a positive correlation between sRAGE levels and the interval from diagnosis to delivery in both groups. This finding suggests a protective function of RAGE. A protective role of increased sRAGE levels in threatened preterm labor was also found by Bastek et al. who analyzed plasma sRAGE levels in a large group of women (n = 529) with the threat of premature labor \[[@CR42]\]. They found lower sRAGE levels in patients who gave birth prematurely compared with those who delivered at term. The authors concluded that evaluation of sRAGE may be a useful marker of premature labor, which is consistent with our findings. Germanova et al. showed decreased sRAGE levels in pregnant women suffering from threatened preterm delivery and from preeclampsia compared with healthy pregnant women, indicating a protective role of RAGE \[[@CR66]\]. Both of the complications of pregnancy analyzed by Germanova et al. are characterized by chronic inflammation \[[@CR67], [@CR68]\]. Hajek et al. found lower sRAGE levels in women who were diagnosed with threatened preterm labor compared with those with healthy pregnancies \[[@CR41]\]. They concluded that the presence of symptoms of threatened premature labor was associated with a decrease in RAGE levels. In the fetal membranes, expression of high-mobility group box-1,which is one of the RAGE ligands, is higher in preterm rupture of the membranes than at term, and promotes one of the mitogen-activated protein kinases (p38MAPK) associated with non-infectious inflammatory responses \[[@CR69]\]. However, there are no conclusive data on negative RAGE isoform expression in preterm pregnancy. In our study, there was no association between gestational age and soluble RAGE levels. Based on the fact that premature aging is a reason of preterm delivery \[[@CR70]\], a deficiency of the membrane-negative form of RAGE (dominant-negative RAGE) should be considered as a potential factor of aging of premature fetal tissue \[[@CR63], [@CR70], [@CR71]\]. Our finding of a correlation between sRANKL and sRAGE levels and the latency period from diagnosis until delivery was the reason why we decided to evaluate the prognostic values of sRANKL and sRAGE for diagnosis of preterm labor for both study groups.

Seven days is an accepted cut-off point for the duration of the latency period in group A \[[@CR72]--[@CR74]\]. The sensitivity for sRANKL reached 89.5 % and the specificity was 54.4 %, with a PPV of 63 % and NPV of 85.7 %, while those for sRAGE were 94.7 %, 59.1 %, 66.7 %, and 92.9 %, respectively. Prognostic values of so-called classic risk markers of preterm labor are usually measured in symptomatic patients (i.e., fetal fibronectin and cervical length) and range from 60 % to 100 % \[[@CR74]--[@CR79]\]. Honest et al. analyzed the literature on prognostic values of tests that are used in calculating risk of preterm delivery, taking into account 319 published studies on evaluation of 22 tests \[[@CR77]\]. The authors concluded that, despite the high sensitivity and specificity of investigated factors, such as the history of previous premature delivery, presence of fetal fibronectin in cervico-vaginal discharge, ultrasound cervical length measurements, and the level of some interleukins in amniotic fluid, their accuracy is still inadequate. This conclusionis supported by the fact that the prevalence of premature birth has not decreased.

In our study, the accuracy of sRAGE and sRANKL in group A was 75.6 % and 70.7 %, respectively. A high sensitivity and NPV, with a high accuracy, suggest that sRAGE and sRANKL could be new effective biomarkers of premature labor. The usefulness of detection of these markers in other compartments, such as amniotic fluid and cervical discharge, should also be assessed.

In group B, the 24-h cut-off point for the latency period was established. In most cases, pPROM is associated, as a cause or as a result, with intrauterine infection \[[@CR80]--[@CR83]\]. Spontaneous development of uterine contractility with subsequent completion of preterm delivery in 24 h from pPROM usually indicates rupture of membranes as a consequence of intrauterine infection. In such circumstances, prolongation of pregnancy, especially administration of tocolytic agents, could worsen the neonatal prognosis.

In our study, plasma sRAGE levels showed a low sensitivity (31.8 %), but a high specificity and PPV, both reaching 100 %. This finding suggests that when sRAGE levels lower than the cut-off point are found in a pregnant woman diagnosed with pPROM, completion of delivery in 24 h is practically guaranteed, although normal levels do not exclude the possibility of delivery. All of the prognostic sRANKL test values ranged between 70 % and 75 %. Thereis little information available to determine which pregnant women suffering from pPROM would deliver in a short period of time. Measurement of classic parameters of inflammation, such as CRP, white blood cells, interleukin-6, and others is useful, but not suitable as an ultimate predictor \[[@CR7]--[@CR9], [@CR83]\].

In our study, we found higher sRANKL and esRAGE levels in pregnancies with the diagnosis of pPROM compared with those diagnosed with threatened preterm labor, but with intact membranes. Importantly, these differences could not have been caused by dissimilarity in gestational age because all valuations of parameters were made at a comparable stage of pregnancy (30.9 vs 31.1 weeks of gestation). We also excluded the influence of overt intrauterine infection because we obtained similar values of the white blood cell count, CRP levels, procalcitonin levels and band cell percentage, as well as the effect of glucocorticosteroids because betamethasone was administered to all of the patients. These results could have been due to an effect of increased activation of T-lymphocytes via cytokines in patients with pPROM compared with those with unruptured membranes. This suggests the presence of advanced inflammation in group B, but this was not confirmed by standard laboratory tests.

Analysis of the relationships between levels of sRANKL, OPG, sRAGE, and esRAGE with other parameters used in the diagnosis of premature labor showed a positive relationship between sRAGE levels and gestational age at delivery and birth weight in group A. This finding suggests a protective role of sRAGE in preterm pregnancy \[[@CR41], [@CR66]\].

Notably, in the entire studied population,we found an association between sRANKL levels and the results of cervical microbiological culture. A positive result of the culture was accompanied by elevated sRANKL levels preceding an increase in CRP levels or WBC. This finding may indicate sRANKL activation via pathogen-associated molecular patterns before other manifestations of infection.

The high predictive values for sRANKL and sRAGE that were obtained in both study groups indicate the potential of the usefulness of these markers in the diagnosis of preterm labor. However, our study has limitations, which include the small size of the study groups and theneed for validation.

Conclusions {#Sec6}
===========

Correlations between sRANKL and sRAGE and the latent time from symptoms until delivery, as well as high prognostic values of sRANKL and sRAGE show the usefulness of these parameters in diagnosis of pregnant women with threatened premature labor. Further prospective research on larger study groups is required. A positive correlation between sRAGE levels and gestational age at delivery and birth weight in group A suggests the potential protective role of sRAGE in the pathogenesis of preterm labor. However, the relationship between sRANKL and cervical microbiological culture requires further study. Our finding of higher esRAGE and sRANKL levels in pregnant women suffering from pPROM compared with those whose fetal membranes remain intact suggests that they play a role in the pathogenesis of pPROM. Further research is required to determine the importance of sRANKL and esRAGE on the process of destruction of fetal membranes.

sRAGE

:   Secretory receptors for advanced glycation end products

esRAGE

:   Endogenous secretory receptors for advanced glycation end products

sRANKL

:   Soluble receptor activator of nuclear factor κB ligand

pPROM

:   Preterm premature rupture of the fetal membranes

OPG

:   Osteoprotegerin

TNF

:   Tumor necrosis factor

NF-κB

:   Nuclear factor kappa-B

RANK

:   Receptor activator of nuclear factor kappa-B

RAGE

:   Receptors for advanced glycation end products

MAPK

:   Mitogen-activated protein kinase

AGE

:   Advanced glycation end products

CRP

:   C-reactive protein

Q1--Q3

:   First and third quartile values

SD

:   Standard deviation

ROC

:   Receiver operating characteristic

PPV

:   Positive predictive value

NPV

:   Negative predictive value

AUC

:   Area under the ROC curve

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

RR conceptualized the study and supervised the research team, drafted the full manuscript, and performed statistical analyses. BD, DS, and MB performed immunoassays. AR collected blood samples and helped to draft the manuscript. SK and WM collected blood samples and clinical data. LD and AT participated in the design and coordination of the study. All authors read and approved the final manuscript.

We thank Miroslaw Mochnaczewski who corrected the English grammar and style of our manuscript.
